EPIX Pharmaceuticals, Inc. Form 8-K May 06, 2008

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2008 **EPIX Pharmaceuticals, Inc.** (Exact Name of Registrant as Specified in its Charter) Delaware

(State or Other Jurisdiction of Incorporation)

000-21863

(Commission File Number)

4 Maguire Road, Lexington, Massachusetts

(Address of Principal Executive Offices)

Registrant s telephone number, including area code: (781) 761-7600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

02421

(Zip Code)

04-3030815

(IRS Employer Identification No.)

2

TABLE OF CONTENTS

Item 2.02Results of Operations and Financial Condition.Item 9.01Financial Statements and Exhibits.SIGNATURESEXHIBIT INDEXPress Release dated May 6, 2008

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2008, EPIX Pharmaceuticals, Inc. announced certain financial results for the quarter ended March 31, 2008. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. **Item 9.01** Financial Statements and Exhibits.

- (d) Exhibits:
 - 99.1 Press Release issued by the registrant on May 6, 2008, furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX PHARMACEUTICALS, INC.

May 6, 2008

By: /s/ Kim Cobleigh Drapkin Kim Cobleigh Drapkin Chief Financial Officer

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release issued by the registrant on May 6, 2008, furnished herewith.